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Abstract Data characterizing demographics, treatment
patterns, and clinical outcomes in black patients with
human epidermal growth factor receptor 2 (HER2)-positive
metastatic breast cancer (MBC) are limited. registHER
is a large, observational cohort study of patients
(n = 1,001) with HER2-positive MBC diagnosed
B6 months of enrollment and followed until death, disen-
rollment, or June 2009 (median follow-up of 27 months).
Demographics, treatment patterns, and clinical outcomes
were described for black (n = 126) and white patients
(n = 793). Progression-free survival (PFS) following first-
line therapy and overall survival (OS) were examined.
Multivariate analyses adjusted for baseline and treatment
factors. Black patients were more likely than white patients
to be obese (body mass index C30), to have diabetes, and
to have a history of cardiovascular disease; they were also
less likely to have estrogen receptor or progesterone
receptor positive disease. In patients treated with trast-
uzumab, the incidence of cardiac safety events (grade C3)
was higher in black patients (10.9 %) than in white patients
(7.9 %). Unadjusted median OS and PFS (months) were
significantly lower in black patients than in white patients
(OS: black: 27.1, 95 % confidence interval [CI] 21.3–32.1;
white: 37.3, 95 % CI 34.6–41.1; PFS: black: 7.0, 95 % CI
5.7–8.2; white: 10.2, 95 % CI 9.3–11.2). The adjusted OS
hazard ratio (HR) for black patients compared with white
patients was 1.29 (95 % CI 1.00–1.65); adjusted PFS HR
was 1.29 (95 % CI 1.05–1.59). This real-world evaluation
of a large cohort of patients with HER2-positive MBC
shows poorer prognostic factors and independently worse
clinical outcomes in black versus white patients. Further
research is needed to identify potential biologic differences
that could have predictive impact for black patients or that
could explain these differences.
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Introduction
Previous literature has shown that, while the incidence of
breast cancer in black women is lower than in white women,
black women are more likely to die as a result of the disease
[1–5], are diagnosed at an earlier age, have a higher grade at
diagnosis [3, 4, 6], and have a greater risk of recurrence [4].
One factor associated with this racial disparity is being diag-
nosed at a later stage [1, 3, 7], which may be contributed to by
socioeconomic factors and access to care [3, 7]. Reproductive
variables associated with breast cancer outcome have been
shown to differ between black and white women, including
menopausal status, use of contraception, breast feeding
behaviors [7, 8], and body mass index (BMI) [4, 7, 8]. How-
ever, even after controlling for such factors, disparities in
health outcomes are still apparent, with several studies
revealing potential underlying biologic differences between
black and white breast cancer patients [2, 7]. In particular, a
greater incidence of triple-negative breast cancer (TNBC),
i.e., estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) negative
or basal-like breast cancer, has been demonstrated in black
women [2, 3], even when controlling for age and BMI [4].
Though data are limited, several inherited genetic factors may
contribute to this biologic association; Olopade and col-
leagues have associated specific germline BRCA1 mutations
with high-risk African American kindreds [9].
About 20–25 % of breast cancers have overexpression
of HER2 [10, 11] which is both prognostic and predictive
of treatment benefit. Overexpression is associated with a
higher risk of and a shorter time to relapse, as well as
poorer prognosis, worse survival, and a higher likelihood of
response to both specific chemotherapy regimens and
biologic therapy targeted to HER2 [2, 10, 12]. Data char-
acterizing HER2 positive metastatic breast cancer (MBC)
in black patients are limited. The objective of this analysis
was to examine demographics, treatment patterns, and
clinical outcomes in black and white patients with HER2-
positive MBC in the registHER observational cohort.
Methods
registHER study design
The registHER study (NCT00105456; clinicaltrials.gov) is
a multicenter, prospective, observational, US-based cohort
study of patients with newly diagnosed HER2-positive
MBC (N = 1,023). Patients were diagnosed within
6 months of enrollment and were recruited from commu-
nity and academic settings between December 2003 and
February 2006. Study design and recruitment details are
described elsewhere [13]. The objectives of registHER
were to describe the natural history of disease and treat-
ment patterns for patients with HER2-positive MBC and to
explore associations between specific therapies and patient
outcomes. Patients received care according to their physi-
cians’ standard practice, without study-specified evalua-
tions. Prior or planned treatment with trastuzumab, or any
specific HER2-targeted therapy, was not a requirement for
enrollment. All patients signed an informed consent and
authorized the disclosure of their health information. There
were no exclusion criteria; however, patients who did not
provide informed consent and did not authorize the dis-
closure of health information were excluded.
Patient information was recorded at enrollment and
updated every 3 months. Information collected included
treatment history, sites of progressive disease, tumor
response, survival, cardiac safety (grades 3/4/5), and
adverse events potentially related to the administration of
trastuzumab. First-line treatment patterns are based on
treatment received prior to first disease progression and
may have been given sequentially or concurrently. History
of metabolic disorders, cardiovascular disease (CVD), and
data on cardiac safety were collected using predefined
checkboxes. Cardiac safety events were defined based on
the Common Terminology Criteria for Adverse Events,
version 3.0, and selected based on physician subjective
opinion [14]. The schedule for tumor assessment and time
of tumor progression was determined by treating physi-
cians per their standards of care.
Statistical analysis
Of the 1,023 patients in the registHER cohort, 22 did not
receive any treatment during the study and were excluded
from the analysis. Due to small numbers, Hispanic patients
(n = 56), Asian/Pacific Islander patients (n = 18), and
patients classified as ‘‘other’’ races (n = 8) were also
excluded. Ultimately, 126 black patients and 793 white
patients were included in this study for which demo-
graphics, treatment patterns, and clinical outcomes were
described (n = 919).
Progression-free survival (PFS) and overall survival
(OS) from time of diagnosis of MBC were analyzed using
the Kaplan–Meier method. Patients without a record of
disease progression or death were censored at the last
followup date or at the data lock date (June 15, 2009),
whichever occurred earlier. Multivariate Cox regression
models were used to generate hazard ratios (HRs) and
95 % confidence intervals (CIs) to assess the effect of race
462 Breast Cancer Res Treat (2013) 141:461–470
123
(black vs. white) on survival outcomes, while adjusting for
clinically significant baseline treatment and prognostic
factors. Multivariate models were adjusted for baseline
factors including age at enrollment, BMI, Eastern Coop-
erative Oncology Group (ECOG) performance status,
serum albumin level, tumor ER/PR status, site of metastatic
disease (adjusted using a hierarchical approach, i.e., [1]
central nervous system [CNS], [2] bone only or bone plus
breast, [3] visceral/other, and [4] node/local), number of
metastatic sites, stage of disease at initial diagnosis, history
of underlying CVD, and history of other underlying non-
cardiac comorbid conditions. The final multivariate models
further adjusted for first-line treatment variables among
patients, including receipt of trastuzumab, taxanes, and
hormonal therapy. Differences in PFS and OS for black
versus white patients were also investigated within sub-
categories of baseline and clinical characteristics, as well
as treatment factors.
Results
Patient characteristics
Baseline demographics and clinical characteristics for the
black and white patients who were followed until death,
disenrollment, or the June 2009 data lock date are shown in
Table 1. Black patients were more likely to have discon-
tinued due to death and loss to followup compared with
white patients (62.7 vs. 53.1 % and 8.7 vs. 4.9 %,
respectively). The median follow-up time was 21.0 months
for black patients and 28.4 months for white patients.
Black patients were slightly younger, had a higher preva-
lence of obesity (50.8 vs. 32.4 %), and had more than twice
the prevalence of diabetes (13.5 vs. 6.4 %) at baseline than
white patients. In addition, twice as many black patients
had a history of underlying CVD at baseline than did white
Table 1 Baseline demographic and clinical characteristics of black
and white patients at diagnosis of MBC
Characteristic Black
patients
(n = 126)
White
patients
(n = 793)
Median follow-up, months 21.0 28.4
Median age, years (min–max) 50 (20–90) 54 (22–92)
Sex, n (%)
Female 125 (99.2) 784 (98.9)
BMI, kg/m2
\30 62 (49.2) 536 (67.6)
C30 64 (50.8) 257 (32.4)
History of diabetes, n (%) 17 (13.5) 51 (6.4)
History of underlying CVD (any),a
n (%)
38 (30.2) 125 (15.8)
Arrhythmia 5 (4.0) 16 (2.0)
Congestive heart failure 4 (3.2) 10 (1.3)
Hypertension with complications 14 (11.1) 33 (4.2)
Angina 1 (0.8) 2 (0.3)
Myocardial infarction 3 (2.4) 16 (2.0)
Peripheral vascular disease 2 (1.6) 10 (1.3)
Other underlying cardiac disease 26 (20.6) 65 (8.2)
Site of metastatic disease at diagnosis, n (%)
Any CNS 11 (8.7) 57 (7.2)
Bone only or bone plus breast 19 (15.1) 114 (14.4)
Visceral 79 (62.7) 487 (61.4)
Node/local 17 (13.5) 133 (16.8)
Other sites 0 (0.0) 2 (0.3)
ECOG performance status at diagnosis, n (%)
0–1 54 (42.9) 366 (46.2)
2? 12 (9.5) 43 (5.4)
Unknown/missing 60 (47.6) 384 (48.4)
ER/PR status, n (%)
ER-positive or PR-positive 53 (42.1) 434 (54.7)
ER-negative and PR-negative 69 (54.8) 329 (41.5)
Unknown 4 (3.2) 30 (3.8)
Clinical stage at initial diagnosis, n (%)
Stage I–III, MBC B12 months after
initial diagnosis
23 (18.3) 98 (12.4)
Stage I–III, MBC [12 months after
initial diagnosis
64 (50.8) 484 (61.0)
Stage IV 39 (31.0) 211 (26.6)
a Patients could be counted in multiple CVD categories
BMI body mass index, CVD cardiovascular disease, CNS central
nervous system, ECOG Eastern Cooperative Oncology Group, ER
estrogen receptor; max maximum, MBC metastatic breast cancer, min
minimum, PR progesterone receptor
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Fig. 1 Select clinical characteristics in black and white patients at the
time of metastatic breast cancer diagnosis. BMI body mass index,
CVD cardiovascular disease, ER estrogen receptor, PR progesterone
receptor
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patients (30.2 vs. 15.8 %) (see Table 1; Fig. 1). Among
black patients, hypertension with complications (11.1 %)
and other cardiac diseases (20.6 %) were the most com-
monly reported CVD conditions.
The distribution of sites of metastatic disease at diag-
nosis was similar for black and white patients, with visceral
sites being the most common and CNS being the least
common for patients of both races. More black patients
than white patients, however, had an ECOG performance
status of C2 at diagnosis, had ER/PR-negative disease, and
presented with de novo stage IV MBC or recurrent stage IV
MBC within 12 months of initial stage I–III diagnosis (see
Table 1).
Adjuvant treatment patterns in patients with recurrent
disease
Treatment patterns in black and white patients with
recurrent disease were similar (Table 2). Among these
patients, the majority received adjuvant systemic therapy
(66.7 % of black patients, 75.4 % of white patients).
Approximately 7 % of both black and white patients
received neoadjuvant or adjuvant trastuzumab.
Treatment patterns prior to first disease progression
Initial regimens for MBC usually included trastuzumab,
and its percentage of use was comparable between black
and white patients (81 and 84 %, respectively). Consistent
with the observed difference in ER/PR statuses, more black
patients received chemotherapy and fewer received hor-
monal therapy with or without chemotherapy than white
patients (Table 3).
In patients who did not receive a trastuzumab-based
regimen as first-line treatment, fewer black patients
received chemotherapy only or were untreated, while more
black patients received hormonal therapy or combined
chemotherapy and hormonal therapy than white patients
(see Table 3). The use of anthracycline and cumulative
dose were comparable between black and white patients
(data not shown).
Cardiac safety outcomes
Reported grade C3 cardiac events in black and white
patients treated with trastuzumab (in any line) are shown in
Table 4. There was a slightly higher incidence of grade C3
cardiac events in black patients (13/119 [10.9 %]) than in
white patients (59/746 [7.9 %]). The incidence of conges-
tive heart failure was 4.2 % (n = 5) in black patients and
1.6 % (n = 12) in white patients.
When stratified by underlying disease history, black
patients treated with trastuzumab and with a history of
diabetes, hypertension with complications, or CVD were
more likely to have cardiac safety events than white
Table 2 Early-stage treatment patterns in black and white patients
with recurrent disease
Treatment, n (%) Black patients
(n = 87)
White patients
(n = 582)
Neoadjuvant systemic therapy 22 (25.3) 118 (20.3)
Adjuvant systemic therapy 58 (66.7) 439 (75.4)
Neoadjuvant/adjuvant trastuzumab 6 (6.9) 44 (7.6)
Patients diagnosed in stages 0–III only or with missing clinical cancer
stage
Table 3 Treatment patterns for MBC prior to first disease progres-
sion among black and white patients
Treatment, n (%) Black
patients
White
patients
Trastuzumab-based first-line
regimensa
(n = 102) (n = 670)
With chemotherapy only 79 (77.5) 438 (65.4)
With hormonal therapy only 5 (4.9) 42 (6.3)
With chemotherapy and
hormonal therapy
12 (11.8) 138 (20.6)
Trastuzumab alone 6 (5.9) 52 (7.8)
Non-trastuzumab-based first-line regimens (n = 24) (n = 123)
Chemotherapy only 9 (37.5) 63 (51.2)
Hormonal therapy only 10 (41.7) 44 (35.8)
Chemotherapy and hormonal
therapy
4 (16.7) 6 (4.9)
Untreated 1 (4.2) 10 (8.1)
a Those in the trastuzumab-based first-line regimens are defined as
patients receiving C21 days of trastuzumab in first-line therapy
MBC metastatic breast cancer
Table 4 Incidence of reported cardiac adverse events (grades C3) in
black and white patients treated with trastuzumab
Adverse event, n (%) Black patients
(n = 119)
White patients
(n = 746)
Any 13 (10.9) 59 (7.9)
Angina pectoris 0 (0.0) 2 (0.3)
Atrial arrhythmia 1 (0.8) 4 (0.5)
Cardiac disorder (NOS) 2 (1.7) 11 (1.5)
Congestive heart failure 5 (4.2) 12 (1.6)
Left ventricular dysfunction 3 (2.5) 22 (2.9)
Myocardial infarction 2 (1.7) 2 (0.3)
Pericardial effusion 0 (0.0) 5 (0.7)
Ventricular arrhythmia 0 (0.0) 1 (0.1)
NOS not otherwise specified
464 Breast Cancer Res Treat (2013) 141:461–470
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patients with the same conditions. Specifically, of the black
patients who reported a history of diabetes and who had
received C1 dose of trastuzumab (n = 15), three (20.0 %)
reported any cardiac safety event compared with four white
patients (n = 48; 8.3 %). Similarly, of the black patients
who reported a history of hypertension with complications
and who had received C1 dose of trastuzumab (n = 14),
two (14.2 %) had any cardiac safety event compared with
two white patients (n = 29; 6.9 %). A history of CVD
appeared to have less of an impact; of the black patients
with any history of CVD and who had received C1 dose of
trastuzumab (n = 36), five patients (13.9 %) had a cardiac
safety event compared with 12 white patients (n = 117;
10.3 %).
Efficacy and clinical outcomes
The unadjusted median first-line PFS was substantially
lower among black patients than among white patients
(7.0 months [95 % CI 5.7–8.2] vs. 10.2 months [95 % CI
9.3–11.2]; Fig. 2a). Unadjusted median OS was also sub-
stantially lower among black patients than among white
patients (27.1 months [95 % CI 21.3–32.1] vs.
37.3 months [95 % CI 34.6–41.1]; Fig. 2b).
To determine whether race had an effect on survival
independent of baseline prognostic and treatment factors,
we conducted a multivariate analysis controlling for base-
line demographics, treatment patterns, and clinical char-
acteristics. After adjusting for these factors, black patients
Time since metastatic diagnosis (months)
Time since metastatic diagnosis (months)
White
Black
582 393 268 202 154 126 96 52 33 12 5 0 0
85 50 28 18 16 9 7 4 2 2 0 0 0
793 764 701 623 538 481
61
407 357 228 110 39 13 0 0
126 121 109 90 75 48 36 23 13 4 1 1 0
Number at risk
Race: WhiteBlack
Median PFS (months)
95% CI
Unadjusted HR (95% CI), 1.353 (1.110–1.648) 
Log rank test P value =  0.003 
White
10.2
(9.3–11.2)
Black
7.0
(5.7–8.2)
b
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)
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Fig. 2 Kaplan–Meier plots
showing first-line a PFS and
b OS since diagnosis of
metastatic breast cancer in black
and white patients. CI
confidence interval, HR hazard
ratio, OS overall survival, PFS
progression-free survival
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had a significantly greater risk for disease progression
compared with white patients (adjusted HR, 1.29; 95 % CI
1.05–1.59; P = 0.015), as well as a significantly greater
risk of death (adjusted HR, 1.29; 95 % CI 1.00–1.65;
P = 0.049).
In PFS and OS analyses within subcategories of baseline
and clinical characteristics (ER/PR status, BMI category,
history of CVD, other disease history, metastatic site, and
stage at initial diagnosis), as well as treatment patterns
(first-line trastuzumab or adjuvant trastuzumab; taxanes or
anthracyclines for metastatic disease), the median PFS and
OS consistently favored white patients (Figs. 3, 4). There
was a trend toward poorer PFS and OS in black patients
compared with white patients for both ER/PR-positive and
ER/PR-negative statuses.
Among patients with disease progression after first-line
therapy for advanced disease, rates of metastasis to node/
local sites were nearly twice as high in black patients (22.2
vs. 13.0 %) as in white patients, while rates of metastases
to bone only or bone plus breast were approximately twice
as high in white patients as in black patients (21.1 vs.
10.2 %, respectively). Black and white patients had similar
rates of metastases to CNS sites (18.5 vs. 20.8 %), visceral
sites (47.2 vs. 43.9 %), and other sites (1.9 vs. 1.1 %),
respectively.
Discussion
In this national registry study conducted in a real-world
setting of patients with HER2-positive MBC, black patients
were found to have more adverse prognostic factors com-
pared with white patients, including the greater BMI and a
higher proportion of ER/PR-negative tumors. These
White patients Black patients
ER/PR status Positive   487 434 11.2 53 6.8 0.69 (0.51–0.93)
)90.1–36.0(38.00.7968.8923893evitageN
)63.1–41.0(44.07.741.210343nwonknU
BMI category <25   298 269 10.2 29 6.9 0.82 (0.54–1.23)
)87.0–73.0(45.03.6235.1166289203<ot52
)21.1–36.0(48.04.7563.985232303≥
CVD history No   756 668 10.2 88 7.4 0.80 (0.63–1.01)
)88.0–14.0(06.08.5833.01521361seY
Other disease history No   660 576 10.1 84 7.2 0.74 (0.58–0.94)
)50.1–35.0(47.09.6244.01712952seY
Metastatic site Any CNS     68  57   7.6 11 6.2 0.87 (0.44–1.71)
Bone and/or breast   133 114 10.4       19        13.8 1.10 (0.64–1.90)
)78.0–35.0(86.08.6972.01784665larecsiV
)90.1–73.0(36.08.6716.11331051lacol/edoN
———5.8122setisrehtO
Stage at initial diagnosis IV 11 12.6        39      11.9 0.82 (0.57–1.19)
I–III, met ≤12 months    121 98 9.5 23 5.4 0.48 (0.30–0.78)
I–III, met >12 months
   250      2
   548      484 9.4 64 7.0 0.76 (0.58–1.00)
)36.1–56.0(30.16.4423.3321741oN
)98.0–75.0(17.06.72014.11076277seY
)78.0–45.0(96.04.6583.9555046oN
7292seY 10.0  2 8.2 0.50 (0.12–2.19)
)03.1–85.0(78.07.7923.9102032oN
295986seY 10.7 97 6.8 0.71 (0.56–0.89)
676587oN         9.9       109 7.0 0.78 (0.63–0.96)
)19.0–23.0(45.07.6715.11711431seY
0.1 0.5 21
HR
3 5
Variable Category Total N n Median n Median HR (95% CI) patients    patients   White                   Black
  Favors                 Favors
First-line 
trastuzumab therapy
Adjuvant trastuzumab 
therapy
Taxanes as 
metastatic treatment
Anthracyclines as 
metastatic treatment
Fig. 3 Analysis of progression-
free survival (PFS) by baseline
characteristics and treatment
patterns in black and white
patients. BMI body mass index,
CI confidence interval, CNS
central nervous system, CVD
cardiovascular, ER estrogen
receptor, HR hazard ratio, met
metastases, PR progesterone
receptor
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differences in prognostic factors may have contributed to
the observed decrease in PFS following first-line therapy
(unadjusted median: 7.0 months [95 % CI 5.7–8.2] vs.
10.2 months [95 % CI 9.3–11.2]), and OS (unadjusted
median: 27.1 months [95 % CI 21.3–32.1] vs. 37.3 months
[95 % CI 34.6–41.1]) in black patients compared with
white patients. Multivariate analyses confirmed that, after
adjustment for differences in prognostic factors, black
patients had a 30 % greater risk of disease progression in
the first-line setting compared with white patients, as well
as a 30 % increase in risk of death.
Black patients in this study had a higher prevalence of
obesity and diabetes; both metabolic disorders have inde-
pendently been associated with breast cancers that exhibit
aggressive biological characteristics and have poor
prognoses [15]. Obesity and diabetes share similar bio-
logical mechanisms for their associations with breast can-
cer. In addition, in line with current population-based,
epidemiologic data [16, 17], black patients in this study had
a higher rate of underlying CVD at baseline compared with
white patients and were more likely to present with de novo
stage IV MBC or recurrent stage IV MBC within
12 months of initial stage I–III diagnosis. However, black
patients consistently demonstrated poorer outcomes, even
after adjusting for differences in BMI, the prevalence of
underlying CVD between black and white patients, and
stage at initial diagnosis.
The unexplained poorer outcomes in black patients with
HER2-positive MBC, despite controlling for prognostic
factors, suggest that other influences, in particular those
White patients Black patients
ER/PR status Positive   487      434 41.7 53 32.4 0.76 (0.51–1.13)
)00.1–35.0(37.07.32964.13923893evitageN
)98.1–12.0(46.02.2248.820343nwonknU
BMI category <25   298      269 36.5 29 25.5 0.72 (0.45–1.17)
)47.0–03.0(74.07.32235.1466289203<ot52
)32.1–95.0(58.00.23561.7385232303≥
CVD history No   756      668 39.5 88 30.5 0.79 (0.59–1.06)
)78.0–53.0(65.02.32835.13521361seY
Other disease history No   660      576 39.5 84 28.4 0.76 (0.56–1.03)
)29.0–14.0(16.03.12248.33712952seY
Metastatic site Any CNS     68       57 24.4 11 18.7 0.67 (0.32–1.39)
Bone and/or breast   133      114 — 19 47.2 1.15 (0.49–2.70)
)79.0–35.0(27.05.52971.63784665larecsiV
)08.0–32.0(34.08.22713.64331051lacol/edoN
————22setisrehtO
Stage at initial diagnosis IV   250      211 42.1 39 30.8 0.70 (0.45–1.11)
I–III, met ≤12 months 121       98 31.7 23 15.4 0.55 (0.32–0.95)
I–III, met >12 months   548      484 36.0 64 27.1 0.76 (0.54–1.06)
No   147      123 28.7 24 20.5 0.58 (0.34–0.99)
)79.0–65.0(47.08.032019.83076277seY
No   640      555 34.1 85 26.6 0.72 (0.54–0.96)
)48.0–30.0(71.05.2227.547292seY
No   230      201 34.6 29 20.3 0.54 (0.34–0.88)
)99.0–75.0(57.05.03795.93295986seY
No   785      676       35.5      109 26.7 0.76 (0.58–0.99)
)58.0–62.0(74.01.72713.34711431seY
HR
Variable      Category Total N n Median n Median HR (95% CI) patients patients
0.1 0.5 21 3 5
   White             Black
  Favors           Favors
First-line 
trastuzumab therapy
Adjuvant trastuzumab 
therapy
Taxanes as 
metastatic treatment
Anthracyclines as 
metastatic treatment
Fig. 4 Analysis of overall
survival (OS) by baseline
characteristics and treatment
patterns in black and white
patients. BMI body mass index,
CI confidence interval, CNS
central nervous system, CVD
cardiovascular, ER estrogen
receptor, HR hazard ratio, met
metastases, PR progesterone
receptor
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underlying tumor and host biology, may play a role in the
etiology and health outcomes of patients with HER2-
positive breast cancer. One illustration of this can be
observed in patients with tumors that are hormone recep-
tor-negative, which are associated with poorer prognosis
compared with hormone receptor-positive tumors [18].
Consistent with the findings in registHER, data from the
large, population-based Surveillance, Epidemiology, and
End Results (SEER) database have shown that African
American breast cancer patients are more likely to have
ER/PR-negative tumors than European American [19] and
non-Hispanic white breast cancer patients [20].
Interestingly, while black patients in the registHER
cohort of HER2-positive patients were more likely to have
ER/PR-negative disease compared with white patients,
there was a trend toward worse outcomes in black patients
within both the ER/PR-positive and ER/PR-negative sub-
sets. While the literature on this finding is limited, an early-
stage analysis from a recent, large, randomized trial pop-
ulation treated with anthracycline- and taxane-containing
chemotherapy found that racial differences in outcome
were observed primarily in the ER-positive group but not
in the ER-negative or HER2-positive groups [21].
There is evidence demonstrating that there are racial/
ethnic differences in breast cancer molecular subtypes in
addition to HER2-positive disease, as well as gene altera-
tions, which have been associated with breast cancer out-
comes. TNBC, which is associated with poor prognosis, an
aggressive and early pattern of metastases, and limited
therapeutic options [22], occurs at a higher rate in indige-
nous African women [3], as well as in African American
women [2, 4, 23, 24], compared with white women. In a
recently completed sequence analysis of 434 breast cancers
in Nigerian patients, high frequencies of BRCA1 and
BRCA2 mutations were found (7.1 and 3.9 %, respec-
tively), and 16 different BRCA1 mutations were detected
[25]. Alterations in p53 were significantly more common in
African American women than in white women (odds ratio,
4.00; 95 % CI 1.77–9.01) in a study of 247 tumor samples,
even after adjustment for disease stage at diagnosis and
other prognostic factors [26]. In 141 tumor tissue samples
analyzed from 72 African American and 69 Latina women
with breast cancer, more than 70 % of the patients with
HER2-positive disease had elevated Akt levels, a level
higher than reported for other ethnic groups in most studies
[27].
Given the increased prevalence of poor prognosis
molecular subtypes and genetic alterations in black women
with breast cancer, and the unexplained unfavorable out-
comes in black patients in registHER, the current hypoth-
esis-generating descriptive study suggests that expanded
research into the role of the biology of HER2-positive
MBC across race/ethnicity may provide an improved
understanding of the etiology of these observations and
could identify possible new targets for therapy.
To determine if racial disparities were evident for
trastuzumab-associated cardiac safety events in registHER,
reported cardiac safety events were compared in white and
black patients treated with trastuzumab. Because the
number of events in the analysis was small, results should
be interpreted with caution. The incidence of cardiac safety
events (collected via predefined checkboxes and physician
subjective opinion) was slightly greater in black patients
than white patients (10.9 vs. 7.9 %, respectively), as was
the incidence of congestive heart failure (4.2 vs. 1.6 %,
respectively). The contributing factors to this modest dif-
ference are unknown, but they are likely to include a higher
incidence of hypertension that requires treatment in black
vs. white patients, as it is known to be a risk factor for
trastuzumab-induced cardiac toxicity [28]. Additional
research is needed to investigate risk factors for cardiac
toxicity by race among patients receiving trastuzumab.
The fact that socioeconomic data were not collected in
registHER, and therefore data could not be adjusted for
socioeconomic status in this analysis, is a weakness of the
study. Socioeconomic factors like account for some pro-
portion of breast cancer outcome disparities, but a
majority of pooled and population-based studies show a
persistence of survival differences in black patients and
white patients after adjustment for socioeconomic factors
[7, 29]. Interestingly, despite the observed increase in
breast cancer mortality in African American breast cancer
patients, these patients are more likely to experience
delays in completion of adjuvant chemotherapy, are more
likely to receive potentially inappropriate and substandard
healthcare, are less likely to undergo preventive cancer
screening, and are less likely to participate in clinical
trials [7, 30].
In addition to the lack of socioeconomic data in regis-
tHER, an inherent limitation of this study is possible
‘‘confounding by indication’’ because of the nonrandom-
ized, observational nature of the registHER study. The
analysis may also include possible residual confounding
due to the inability to control for prior treatments, treat-
ment compliance, tumor size, menopausal status, and New
York Heart Association Functional Classification. CVD
and cardiovascular safety data were collected via prede-
fined checkboxes and physicians subjective opinion rather
than via validated methods. Also, the overall findings
should be interpreted with caution due to the small number
of events. Limited information was collected for cause of
death (options included only ‘‘cancer’’ and ‘‘other’’) and
was missing for 32/538 deaths ([5 % of deaths) in the
registHER cohort (n = 1,001), which precluded the cal-
culation of breast cancer-specific mortality rates in this
study.
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Conclusions
These real-world data from the US-based registHER study
show consistently poorer outcomes in black patients with
HER2-positive MBC compared with white patients with
the same disease, outcomes which were not explained by
the higher prevalence of high-risk prognostic factors
among black patients. These findings suggest a need to
better understand possible underlying biological differ-
ences that could have a predictive or prognostic signifi-
cance for black patients with HER2-positive MBC. Further
prospective research is now ongoing through a second
disease-based registry, SystHERs, which includes the col-
lection of archival tumor and germline DNA to better
understand not only the biology of resistance but also racial
and other host differences, treatment patterns, and out-
comes for patients with HER2-positive MBC.
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